Cortex Pharmaceuticals, Inc.
Cortex Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurodegenerative, and neurological and psychiatric disorders. The company principally focuses on AMPAKINE molecules, targeted towards human central nervous system diseases. The company classifies its operations into four regions namely the US, Europe, Asia and Middle East. The company is headquartered at Irvine in California, the US.
Recently, Cortex Pharmaceuticals entered into an agreement with Biovail Laboratories International SRL pursuant to which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing related to respiratory depression and vaso-occlusive crises associated with sickle cell disease.